Interestingly, our previous phase III BEYOND trial has showed that bevacizumab plus carboplatin and paclitaxel could achieve PFS of 12.4 months PFS in patient with non-squamous NSCLC and EGFR mutation [19], which was similar to the historical data of PFS using EGFR-TKIs as the first-line therapy in NSCLC patients with sensitizing EGFR mutations [2, 3]. Here, EGFR is linked to non-small cell lung carcinoma.